Myocardial Infarction

Acute myocardial infarction (AMI) is one of the most common manifestations of CVD. Percutaneous coronary intervention (PCI) has provided important clinical benefits in the treatment of AMI.  Still, mortality and morbidity related to AMI complications remain important (reinfarction, ventricular rupture, arrhythmias, and heart failure). Recent efforts resulted in numerous approaches for the management of AMI complications such as implantable cardiac defibrillator, new drugs and stem cell-based therapy. The optimal use of this new therapeutics requires tools for the identification of patients that will benefit the most from each approach.

Firalis qualifies new proprietary biomarkers for the early detection of AMI complications and to generate biomarker-based prediction models. Firalis, together with its partners from academia and industry, integrates new technologies and imaging tools to study multiple processes involved in the outcomes of AMI in combination with proprietary BM candidates. This integrated approach should lead to highly performing predictive models in patients post myocardial infarction. These tools should improve the patient‘s management, allow a faster and cost effective clinical development of new drugs by achieving an appropriate stratification of the study populations, and ultimately, help the physician to select the most appropriate therapeutic option.

To identify new prognostic biomarkers in MI patients, the group led by Drs. Y. Devaux and Wagner have designed an approach combining protein interaction networks and microarray analysis of blood cells. This tool identified a set of three genes able to predict significant left ventricular dysfunction with an area under the receiver operating characteristic curve (AUC) of 0.82. These three genes-vascular endothelial growth factor B, thrombospondin-1 and placental growth factor-had a stronger predictive value than the currently proposed prognostic biomarkers such as brain natriuretic peptide and troponin T (AUC of 0.63).

Firalis and Laboratory of Cardiovascular Research of the “Centre de Recherche Public-Santé” in Luxembourg signed an exclusive license agreement and develop new combination of biomarkers to increase the predictive performance of this prognostic tool (link to the press release). Firalis is proceeding with the CE marking of these biomarkers already available for clinical research application. Firalis can provide clinicians with these biomarkers for your regulatory approved clinical studies conducted in patients with myocardial infarction. Submit a request now!